For most entrepreneurs, taking a company public is a milestone. For Leen Kawas, it was something closer to a crucible. The biotech scientist and investor had already spent years navigating the complexities of drug development—cell pathways, clinical trials, regulatory frameworks—when she led Athira Pharma through its IPO in 2020. But stepping into the public markets brought a different kind of complexity. One not rooted in science, but in scrutiny.
By the time Athira debuted on the Nasdaq, Kawas had already distinguished herself as a rare figure in biotech: a scientist-CEO who could speak fluently across disciplines—bench research, capital markets, boardroom strategy. Under her leadership, the company advanced therapies targeting neurodegenerative diseases, built a pipeline, and raised over $400 million across private and public rounds. But the act of going public forced a shift. Not in vision, but in visibility.
Unlike many sectors, biotech IPOs often happen before the product hits the market. Investors are not buying into revenue streams. They are buying into probability. That changes the tempo. It compresses time. Every milestone—trial enrollment, safety readouts, manufacturing scale-up—becomes part of a larger narrative that unfolds in real time, under public observation.
Kawas did not shy away from that tension. She approached it the way she approached science: by breaking it into systems. She built an investor relations strategy that educated rather than marketed. She insisted on clarity of risk. And she prepared her team for the psychological weight of public reporting—not just the technical mechanics of filings, but the cultural shift required to sustain focus under market pressure.
The rewards were real. Going public provided Athira with access to capital at a scale private markets couldn’t match. It expanded visibility, attracted talent, and validated the company’s platform in a crowded neurodegeneration space. But Kawas is quick to note that the IPO was not the finish line. It was an acceleration point. One that made the company more accountable, more exposed, and, in some ways, more vulnerable.
That vulnerability is specific to biotech. In most industries, revenue provides insulation. In biotech, outcomes are binary. A trial succeeds or it doesn’t. A molecule works or it doesn’t. For public companies, that reality gets priced in daily. Kawas learned to navigate that volatility not by chasing sentiment, but by returning to the fundamentals: trial design, data integrity, pipeline prioritization.
The challenge, she says, is not just technical. It’s emotional. The public market rewards boldness—but punishes surprises. Leaders must remain transparent without overpromising, optimistic without drifting into hype. For a scientist trained in empirical thinking, that balance is familiar. For a founder navigating market cycles, it becomes a daily discipline.
After stepping down from Athira, Kawas redirected her energy toward broader impact. As managing general partner of Propel Bio Partners, she now backs other founders navigating the early stages of life science innovation. Her work spans diagnostics, therapeutics, and platform tools, but her lens remains the same: support science with operational excellence. Prepare for complexity early. And don’t mistake funding for readiness. Her interview with Billion Success explores this further.
Her approach is shaped by firsthand experience. She knows what it takes to raise nine-figure rounds. She also knows the strain that comes with turning scientific vision into public accountability. The rewards are substantial—broader access, faster development, amplified visibility—but they are not automatic. They require governance systems that are resilient under pressure. Teams that can absorb uncertainty. Boards that understand both capital and biology.
In this ecosystem, Kawas sees herself as a bridge. Someone who can translate between sectors, coach through inflection points, and help founders design companies that can withstand the demands of growth. She does not glamorize the IPO. She contextualizes it—as a tool, not a goal.
For emerging biotech leaders, that framing matters. The path to the public markets is not linear. It’s a maze of science, timing, and storytelling. Kawas has walked it. She’s made the tough calls—on what to prioritize, how to allocate resources, when to accelerate, and when to pause. That perspective now informs how she evaluates companies, how she supports them, and how she prepares them for the moment when their work moves from the lab to the market—and into the spotlight.
Leen Kawas knows that the IPO is not just a transaction. It’s a transformation. One that demands not only a good product, but a leader who can hold vision and volatility in the same hand. She has done it once. Now, she’s helping others do it better.
Learn more about what Kawas is currently up to at the link below: